Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | DRD3 | P35462 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | LTA4H | P09960 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2512123 | 0.89 | ALDH1A1 (0.55) | ALDH1A1KDM4EPAOXTDP1POLB | |
| SCHEMBL4381607 | 0.88 | ALDH1A1 (0.45) | ALDH1A1KDM4EPAOXTDP1POLB | |
| SCHEMBL18024003 | 0.83 | ALDH1A1 (0.47) | ALDH1A1KDM4EPAOXTDP1POLB | |
| SCHEMBL1469602 | 0.82 | HRH3 (0.44) | ALDH1A1KDM4EMEN1KMT2AHRH3 | |
| SCHEMBL15495130 | 0.81 | ALDH1A1 (0.50) | ALDH1A1KDM4EPAOXTDP1POLB | |
| SCHEMBL5418823 | 0.80 | HRH3 (0.48) | ALDH1A1KDM4EPOLBMEN1KMT2A | |
| SCHEMBL4904859 | 0.80 | ALDH1A1 (0.49) | ALDH1A1KDM4EPAOXTDP1POLB | |
| SCHEMBL1097993 | 0.78 | HTR1A (0.53) | ALDH1A1KDM4EPAOXPOLBUSP2 | |
| SCHEMBL14500230 | 0.78 | KDM4E (0.51) | ALDH1A1KDM4ETDP1HRH3 | |
| SCHEMBL22778298 | 0.78 | ALDH1A1 (0.51) | ALDH1A1KDM4EPAOXTDP1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 156 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1802591-B1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2012-01-11 | — | — | EP | claimed |
| US-20090233924-A1 | Quinazoline derivatives | ASTRAZENECA AB (SE) | 2009-09-17 | — | — | US | claimed |
| US-7501516-B2 | Quinoline derivatives and their use as tyrosine kinase inhibitors | ASTRAZENECA AB (SE) | 2009-03-10 | — | — | US | claimed |
| US-20090036474-A1 | Quinazoline derivatives for use against cancer | PLE PATRICK | 2009-02-05 | — | — | US | claimed |
| EP-1381599-B1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2008-09-24 | — | — | EP | claimed |
| EP-1562955-B1 | QUINAZOLINE DERIVATIVES AS SRC TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2008-02-27 | — | — | EP | claimed |
| US-7262201-B1 | For the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in warm-blooded animals | ASTRAZENECA AB (SE) | 2007-08-28 | — | — | US | claimed |
| US-20070191346-A1 | 3-Cyano-quinoline derivatives | ASTRAZENECA AB | 2007-08-16 | — | — | US | claimed |
| US-7223756-B2 | Quinazoline compounds with therapeutic use | ASTRAZENECA AB (SE) | 2007-05-29 | — | — | US | claimed |
| US-7173136-B2 | 3-Cyano-quinoline derivatives | ASTRAZENECA AB (SE) | 2007-02-06 | — | — | US | claimed |
| EP-1326860-A1 | QUINAZOLINE DERIVATIVES | AstraZeneca AB (SE) | 2003-07-16 | — | — | EP | claimed |
| WO-2003047585-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING BENZOFURANYL SUBSTITUTED 3-CYANOQUINOLINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF SOLID TUMOURS | ASTRAZENECA AB (SE) | 2003-06-12 | — | — | WO | claimed |
| WO-2003045364-A2 | USE OF QUINAZOLINES TO TREAT T-CELL MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2003-06-05 | — | — | WO | claimed |
| WO-2003045943-A1 | QUINAZOLINE COMPOUNDS WITH THERAPEUTIC USE | ASTRAZENECA AB (SE) | 2003-06-05 | — | — | WO | claimed |
| EP-1313727-A1 | QUINAZOLINE DERIVATIVES | AstraZeneca AB (SE) | 2003-05-28 | — | — | EP | claimed |
| WO-2002085895-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2002-10-31 | — | — | WO | claimed |
| WO-2002030926-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2002-04-18 | — | — | WO | claimed |
| WO-2002016352-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2002-02-28 | — | — | WO | claimed |
| EP-1119567-A1 | QUINAZOLINE DERIVATIVES | AstraZeneca AB (SE) | 2001-08-01 | — | — | EP | claimed |
| WO-2000021955-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2000-04-20 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036474-A1 | Quinazoline derivatives for use against cancer | AQP3, AQP1, F12 | ALDH1A1 2449/4885KDM4E 2349/4885PAOX 3196/4885 |
| US-20090233924-A1 | Quinazoline derivatives | AQP1, PGF, F12 | ALDH1A1 2094/4885KDM4E 2801/4885PAOX 2642/4885 |
| US-20070191346-A1 | 3-Cyano-quinoline derivatives | MKI67, CCNA1, CCNT1 | ALDH1A1 1113/4885KDM4E 1779/4885PAOX 3358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.